Immatics Biotechnologies GmbH
64 articles about Immatics Biotechnologies GmbH
GSK has pulled out of its partnership focused on developing T-cell receptor therapeutics for solid tumors with Immatics, the German biotech revealed in its Q3 financial results published Thursday.
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Immatics N.V. provided a business update and reported financial results for the quarter ended September 30, 2022.
Immatics announced plans to raise about $110 million in a common stock offering following the release of promising early-stage data that supports its ACTengine technology platform.
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Immatics N.V. announced a comprehensive preclinical data set for its T cell engaging receptor product candidate IMA402 at the European Society for Medical Oncology Congress 2022 held in Paris, France, from September 9 to 13, 2022.
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
The combination of Opdivo plus Yervoy in addition to chemotherapy demonstrated additional benefits in patient populations who usually have poor prognoses.
Immatics Announces First Quarter 2022 Financial Results and Business Update
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, reported financial results and provided a business update for the quarter ended March 31, 2022.
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor IMA401 for patients with recurrent and/or refractory solid tumors.
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics' experimental cancer drug program, the companies announced Tuesday morning.
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
BioCopy AG announces a collaboration with Immatics N.V. "Immatics" in the field of characterization of T cell receptors.
Immatics Announces Changes to its Board of Directors - May 26, 2021
Tuebingen, Germany and Houston, Texas, May26, 2021 – Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced changes to its Board of Directors.
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Immatics’ second TCR Bispecifics program IMA402 demonstratestumor cell killing in vitro and complete regressions of established tumors in anin vivo tumor model
The next several years will be transformative in the cell and gene therapy space, and Immatics’ Chief Medical Officer Cedrik M. Britten believes his company’s engineered T-cell receptors may play an important role in providing treatment options for cancer patients.
BioSpace Global Roundup, Aug. 20
8/20/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
BioSpace Movers & Shakers, June 5
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Immatics Appoints Cedrik Britten as Chief Medical Officer
Former Head of Oncology Cell Therapy Research Unit at GSK to lead clinical development at Immatics
T cell redirecting cancer company Immatics Biotechnologies entered into a merger agreement with Arya Sciences Acquisition Corp. that will give the Germany-based company a listing on the Nasdaq exchange under the ticker symbol IMTX.
Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies
Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account
Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced it has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.